March 15, 2021 -- AstraZeneca has reaffirmed that its COVID-19 vaccine is safe following concerns that the vaccine increases a person's risk of thrombotic events.
After reviewing all available safety data of the more than 17 million people vaccinated with the Astra Zeneca vaccine in the European Union and in the U.K., the company found no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT), or thrombocytopenia in a particular country or vaccine batch or defined age group or gender.
There have been 15 events of deep vein thrombosis and 22 events of pulmonary embolism reported among those given the vaccine as of March 8, which is lower than what is expected to occur naturally in a general population, according to the company. AstraZeneca will continue to monitor the issue.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
